Articles | Volume 3, issue 5
https://doi.org/10.7150/jbji.30029
© Author(s) 2018. This work is distributed under the Creative Commons Attribution 4.0 License.
Brief report
| 
24 Nov 2018
Brief report |
| 24 Nov 2018
| 24 Nov 2018
Rifampin-Resistant Cutibacterium (formerly Propionibacterium) namnetense Superinfection after Staphylococcus aureus Bone Infection Treatment
Cited articles
Aubin GG, Lavigne JP, Guyomarch B. et al. Staphylokinase and ABO group phenotype:new players in Staphylococcus aureus implant-associated infection development. Future Microbiol. 2015;10:1929–1938.
Aubin GG, Bémer P, Guillouzouic A. et al. Failure of combination therapy for Staphylococcus aureus bone infection: a case of in vivo selection with resistance to rifampicin and fusidic acid. Infect Dis Lond Engl. 2016;48:699–702.
Aubin GG, Portillo ME, Trampuz A. et al. Propionibacterium acnes, an emerging pathogen: From acne to implant-infections, from phylotype to resistance. Med Mal Infect. 2014;44:241–250.
Portillo ME, Corvec S, Borens O, Propionibacterium acnes: an underestimated pathogen in implant-associated infections. BioMed Res Int; 2013. p. 804391. [PMC free article]
